• Cadila Healthcare’s consolidated revenues for the quarter ended December (Q3FY22) were down 3% quarter-on-quarter (QoQ). On a year-on-year (YoY) basis, it witnessed a growth of 2%.
  • Its expenses for the quarter were down 1% QoQ and up 2% YoY.
  • While the pharma company reported a 1% QoQ net profit decline, the same remained flat on a YoY basis.
  • The earnings per share (EPS) of Cadila Healthcare stood at 4.9 during Q3FY22.

Cadila Healthcare’s Financial Statements for Q3FY22:

(Rs, crores) Q3FY21 Q2FY22 Q3FY22 QoQ (%) YoY (%)
Total Income 3,660 3,838 3,716 -3% 2%
Total Expenses 3,070 3,139 3,117 -1% 2%
Profit before tax 590 604 599 -1% 1%
Tax 105 100 111 11% 6%
Profit after tax 501 506 500 -1% 0%
Earnings per share 4.9 4.9 4.9    

Data Source: BSE, Company announcements

Want to get more analysis on Indian listed companies? Open an account and get daily stock research updates from Kotak Securities.

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results